Vertex halts development of diabetes cell therapy after trial failure
Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.
Autoimmune Disorders
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Genentech eyes lupus market for Gazyva with positive Phase III data readout
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases
Candid Therapeutics signs $925m T-cell engager deal with WuXi Biologics
CHMP recommends oral peanut allergy immunotherapy treatment for toddlers
Advanz Pharma’s liver disease drug pulled from European market after court hearing
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
